搜尋結果
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [ 1 ] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. [ 31 ] It contains a recombinant spike protein from the SARS-CoV-2 Omicron variant lineage JN.1.
It is aimed at stimulating resistance to respiratory syncytial virus infection, targeting both adult and infant populations. [9] 2016 saw the company's first phase III trial, the 12,000 adult Resolve trial, [9] for its respiratory syncytial virus vaccine, which would come to be known as ResVax, fail in September. [11]
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations. [ 661 ] [ 662 ]
The Matrix-M adjuvant is used in a number of vaccine candidates, including the malaria vaccine R21/Matrix-M, [1] [11] influenza vaccines, [2] and in the approved Novavax COVID-19 vaccine. [5] [12] In 2021, the R21/Matrix-M malaria vaccine candidate showed a
On 1 November, Taiwan received its second donation of Moderna COVID-19 vaccine from the United States with 1.5 million doses. [72] On 5 November, Taiwan received its eleventh shipment of Pfizer–BioNTech vaccine with 871,700 doses.
The authorized vaccines of this type include the Novavax COVID‑19 vaccine. [19] [103]
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States. The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
